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Abstract
Background: Edema in nephrotic syndrome results from renal retention of sodium and alteration of the
permeability properties of capillaries. Nephrotic syndrome induced by puromycin aminonucleoside (PAN) in rats
reproduces the biological and clinical signs of the human disease, and has been widely used to identify the
cellular mechanisms of sodium retention. Unfortunately, mice do not develop nephrotic syndrome in response to
PAN, and we still lack a good mouse model of the disease in which the genetic tools necessary for further
characterizing the pathophysiological pathway could be used. Mouse resistance to PAN has been attributed to a
defect in glomerular adenosine deaminase (ADA), which metabolizes PAN. We therefore attempted to develop a
mouse line sensitive to PAN through induction of normal adenosine metabolism in their podocytes.
Methods: A mouse line expressing functional ADA under the control of the podocyte-specific podocin promoter
was generated by transgenesis. The effect of PAN on urinary excretion of sodium and proteins was compared in
rats and in mice over-expressing ADA and in littermates.
Results: We confirmed that expression of ADA mRNAs was much lower in wild type mouse than in rat glomerulus.
Transgenic mice expressed ADA specifically in the glomerulus, and their ADA activity was of the same order of
magnitude as in rats. Nonetheless, ADA transgenic mice remained insensitive to PAN treatment in terms of both
proteinuria and sodium retention.
Conclusions: Along with previous results, this study shows that adenosine deaminase is necessary but not
sufficient to confer PAN sensitivity to podocytes. ADA transgenic mice could be used as a background strain for
further transgenesis.
Background
Nephrotic syndrome is defined by abnormal urinary
excretion of proteins leading to hypoalbuminemia.
These biological signs are secondary to alterations of the
glomerular filtration barrier. The primary forms of the
disease correspond to either genetic alterations of pro-
teins involved in the glomerular filtration barrier or to
the idiopathic nephrotic syndrome which is due to a cir-
culating factor that functionally alters the glomerular
barrier. Whatever its etiology, nephrotic syndrome is
always associated with renal retention of sodium which,
along with alterations of the permeability properties of
the capillary wall, promotes ascites and/or edema [1].
The most widely used animal model to study sodium
retention in nephrotic syndrome is a rat model that
reproduces the biological and clinical signs of the
human disease [2,3]. It is induced by a single injection
of puromycin aminonucleoside (PAN), an adenosine
derivative used as an antibiotics and anti-proliferative
drug that also induces nephrotic syndrome in humans.
Previous studies in nephrotic rats have shown that
sodium retention results from stimulation of its reab-
sorption in the aldosterone sensitive distal nephron
[4-6] and from resistance of the terminal collecting duct
to the effect of atrial natriuretic peptide [7,8]. Increased
sodium reabsorption originates in principal cells where
both apical sodium entry via the epithelial sodium
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increased [6,9]. Although ENaC and Na,K-ATPase are
known targets of aldosterone [10,11], and although
plasma aldosterone is increased in PAN nephrotic rats
[3], sodium retention is independent of aldosterone
[6,12]. As a matter of fact, sodium retention is not
accounted for by variations in any endocrine system
s i n c ei ta f f e c t so n l yt h et r e a t e dk i d n e yi nu n i l a t e r a l
PAN-induced nephrotic syndrome [5]. Several alternate
hypotheses have been proposed to explain sodium
retention, but they have not been unambiguously vali-
dated, as this would require genetic invalidation of
hypothesized target genes. Unfortunately mice do not
develop nephrotic syndrome in response to PAN, and
no mouse model of nephrotic syndrome featuring the
signs of the human disease exists yet.
Interspecies differences in sensitivity to PAN have
been associated with differences in the adenosine meta-
bolism pathway. Thus, Nosaka et al. [13] showed that
sensitivity to PAN of different species was correlated
with their renal adenosine deaminase (ADA) activity:
Among the species they studied, rats and mice displayed
the highest and lowest ADA activity respectively, and
were the two prototypes of PAN sensitivity and resis-
tance in term of proteinuria. The same group also
showed that pre-treatment of rats with the ADA inhibi-
tor 2’-deoxycoformycin prevented PAN-induced protei-
nuria and glomerular lesions [13]. More recently, Xia et
al. [14] showed that adenosine and PAN enter cells via
the plasma membrane amine transporter (PMAT) which
is expressed specifically in podocytes in both rat and
human. Overexpression of PMAT in MDCK cells
increased their sensitivity to PAN, an effect which was
abolished by decynium 22, a potent inhibitor of PMAT
[14]. Thus, low expression of PMAT in mouse podocyte
might also account for PAN resistance.
In an attempt to develop a mouse line sensitive to PAN
through induction of normal adenosine metabolism in
podocytes, we sought to determine whether or not
PMAT expression in mouse glomerulus might be limit-
ing in order to engineer mice expressing ADA and, if
necessary PMAT, in their podocytes through transgenesis
using a podocyte specific promoter. The sensitivity to
PAN was evaluated on the basis of its ability to induce
urinary excretion of proteins and to reduce sodium
excretion in transgenic mice as compared to littermates.
Rats were studied in parallel as positive controls.
Methods
Transgenesis plasmid construction
Plasmid containing the human NPHS2 promoter was
kindly provided by C Antignac (Hôpital Necker, Paris).
Oligonucleotide primers were designed to PCR amplify
a 2.6 kb fragment of NPHS2 promoter located upstream
the NPHS2 initiation codon (sense: 5’-GAAGATCT-
CAGCTGGCCCTCCTATTTAGTCTCTCTGCCACC-3’
and antisense: 5’-CCCGGCAGCTCTGACCATGG-
TACCCC-3’). The sense and antisense primers con-
tained BglII-PvuIa n dKpnI sites respectively. This
promoter fragment was cloned at the BglII and KpnI
sites of pCi vector (Promega) in place of CMVI.E pro-
moter and intron sequences. Similary, oligonucleotide
primers were designed to PCR amplify from mouse kid-
n e yc D N A st h ef u l ll e n g t hm o u s eA D Ac D N A( s e n s e :
5’-AAGGAAAAAAGCGGCCGCGGAACCATGGCC-
CAGACACCCGCATTCAACAA-3’,a n da n t i s e n s e :5 ’-
TTCTCCTTTTGCGGCCGCCTAAGCATAATCCGG-
TACATCATACGGGTATTGGTATTCTCTGTAGA-
GCCGT-3’). These two primers contained a NotIs i t e ,
and the antisense primer also encoded a hemagglutinin
tag before the stop codon. The ADA cDNA was cloned
at NotIs i t eo fp C iv e c t o r ,d o w s t r e a mt h eN P H S 2p r o -
moter fragment. Finally, the modified pCi vector was
digested with NcoI to remove the vector fragment
remaining between the promoter and the ADA cDNA.
The sequences of all constructs were checked by
sequencing. After amplification and PvuId i g e s t i o n ,t h e
transgenesis plasmid (Figure 1) was purified. Generation
of transgenetic mice in FVB/n genetic background was
performed by the Service d’Expérimentation Animale de
Transgénèse (CNRS UPS 44, Villejuif, France). Genera-
tion of this mouse transgenic line and its study were
performed with the approval of the French Ministère de
l’Enseignement Supérieur et de la Recherche (approval #
5197, april 16, 2009).
Transgene detection by PCR
Transgenic mice were identified by PCR on DNA recov-
ered from tail biopsies. Tail fragments of 1 month-old
Figure 1 Schematic structure of the NPHS2-promoter/ADA
transgene. The transgene construct carried a 2.6-kb DNA fragment
located upstream the translated region of the human NPHS2
(hatched) gene followed by the mouse ADA cDNA (dotted). A HA-
tag was introduced at the 3’ end of ADA (black), just before the
stop codon. Finally, the poly-adenylation (grey) sequence
corresponds to the SV40 Late poly(A) from pCi vector. Arrows
indicate the location of primers used for PCR genotyping of mice.
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(100 mM Tris-HCl pH 8.5, 200 mM NaCl, 10 mM
EDTA, 0.2% SDS) containing 0.66 mg/ml proteinase K
(Invitrogen). Proteinase K was inactivated 5 min at 95°C.
The transgene was identified by PCR (GoTaq® DNA
polymerase, Promega, 35 cycles, Tm: 65°C) using pri-
mers located in the promoter and in ADA regions
respectively (Figure 1): sense, 5’-TGCAGACACG-
CACTTTTCAA-3’; reverse, 5’-GCCATCAAGAG-
GATCGCCTA-3’
Microdissection
Glomerulus, cortical collecting ducts (CCD) and proxi-
mal convoluted tubules (PCT) were dissected from lib-
erase-treated kidneys (Blendzyme 2, Roche Diagnostics)
as previously described [15]. Briefly, the left kidney was
perfused in situ w i t h6m lo fH a n k ’ss o l u t i o ns u p p l e -
mented with 1 mM glutamine, 1 mM pyruvate, 0.5 mM
MgCl2, 0.1% bovine serum albumin, 20 mM Hepes, and
0.015% liberase (w/v), pH 7.4. Thin pyramids were cut
from the kidney and incubated in 0.006% liberase solu-
tion for 20-25 min at 30°C and thoroughly rinsed in
microdissection solution supplemented with a cocktail
of protease inhibitors (Complete EDTA-free, Roche
Diagnostics) when used for western blot. For RNA
extraction, tissues were isolated under Rnase-free
conditions.
Western blot analysis
After microdissection, po o l so f5 0t o6 0g l o m e r u l u s ,
PCT or CCD were solubilized at 95°C for 5 min after
addition of 2× Laemmli. SDS-PAGE was performed on
10% polyacrylamide gels and proteins were transferred
to Hybond™-P membrane (GE Healthcare) using stan-
dard procedure. Blots were blocked in 5% non-fat dry
milk in TBS-Nonidet P-40 buffer (50 mM Tris base,
150 mM NaCl, 0.2% Nonidet P-40) and incubated with
a specific rat anti-HA antibody (Roche diagnostics;
dilution 1/1 500), and incubated with a secondary
horseradish peroxidase-linked anti-rat antibody (Jack-
son Immunoresearch, Ltd). Immunodetection was per-
formed using enhanced chemiluminescence light
detecting kit (Amersham, Arlinghton Heights, IL,
USA).
RNA extraction and RT-QPCR
RNAs were extracted from pools of 50-60 glomerulus
using RNeasy Plus Micro Kit (Qiagen) according to the
manufacturer’s instructions. Reverse transcription was
performed on 80% of glomerular RNA extract using the
first-strand cDNA synthesis kit for reverse transcription-
PCR (Roche Diagnostics), according to the manufac-
turer’s instructions. The remaining 20% of glomerulus
RNA extract were processed in parallel in the absence
of reverse transcriptase and served as controls. No
amplification product was detected in these controls in
any experiment.
Real-time PCR was performed on a LightCycler
(Roche Diagnostics) with the LightCycler 480 SYBR
Green I Master qPCR kit (Roche Diagnostics) according
to the manufacturer’s instructions, except that the reac-
tion volume was reduced to 10 μl. PCR was performed
in the presence of cDNA corresponding to 1 glomeru-
lus. Specific primers (available upon request) were
designed using Light Cycler probe design software II
(Roche Diagnostics).
Animals
All animal experiments were carried out according the
French legislation, under the responsibility of an enabled
experimenter (AD, license #75-699 renewal). Nephrosis
was induced in male Sprague Dawley rats (160-200 g,
Charles River, France) by a single administration of
PAN (150 mg/kg body wt, jugular vein). In mice, PAN
was administered either once or twice (150-300 mg/kg
body wt, retro-orbital or jugular vein injection).
Animals were acclimatized to metabolic cages for at
least two days before PAN administration. 24-h urine
was collected for determination of sodium, creatinine,
and proteins on an automatic analyzer (Konelab 20i,
Thermo, Cergy Pontoise, France). Urinary sodium and
protein excretions were calculated as a function of urin-
ary creatinine excretion. Animals were sacrificed at the
end of the experimental period (6-10 days after PAN
injection).
Determination of ADA specific activity
The method used was previously described by Chinsky
et al. [16]. Rat and mouse kidneys were placed in ice
cold 0.1 M potassium phosphate, pH 7.4 buffer contain-
ing 1 mM 2-mercaptoethanol and were lysed by Poly-
tron. Cell debris were removed by microfuge
centrifugation (10 min at 4°C). Protein content of homo-
genates was estimated by the method of Bradford. ADA
activity was assayed at room temperature in a reaction
mixture containing 0.14 mM adenosine, 50 mM potas-
sium phosphate, pH 7.4 and tissue homogenate. The
decrease in absorbance at 260 nm resulting from deami-
nation of adenosine to inosine was monitored every 10s
with a spectrophotometer and the rate of inosine pro-
duction was determined under initial rate conditions
[17].
Results
Expression of ADA and PMAT in mouse and rat
glomerulus
The expression levels of ADA and PMAT determined
by RT-QPCR in mouse and rat glomerulus were
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of each transcript as:
QK LE f f
Cp =× /
in which K is a transcript-independent constant, L is
the amplicon length, Eff is the PCR efficiency and Cp is
the threshold of fluorescence detection, determined as
the number of PCR cycles at which the reaction fluores-
cence reaches its second derivative maximum [18].
Expression of ADA was very low in the glomerulus of
mouse as compared to that of rat. In contrast, mRNA
expression level of PMAT was ~4-fold higher in mouse
glomerulus than in rat glomerulus, but the difference
was not statistically significant (Figure 2). Thus, as
opposed to ADA, PMAT did not appear to be a limiting
factor for PAN metabolism by mouse podocytes. We
therefore decided to promote normal adenosine metabo-
lism in mouse glomerulus by generating a mouse line
over-expressing ADA in podocytes.
Transgenic mice
For this purpose, a 2.6-kb fragment of DNA located
upstream from the human NPHS2 transcribed region
was selected to drive the expression of ADA in podo-
cytes. This fragment was selected because its gene pro-
duct, podocin, is specifically expressed in podocytes [19]
and because it was previously used successfully to drive
expression of another transgene in these cells [20]. Tran-
genic mice were generated by pronuclear injection in
FVB/n mice. Five transgenic founders were identified by
PCR analysis of genomic DNA, among which one died a
few weeks after birth, one wasu n a b l et or e p r o d u c e ,a n d
one failed to transmit the transgene to its progeny. The
last two founders transmitted the transgene to their pro-
g e n y( m o u s el i n e s2a n d3 )b u to n l yl i n e2e x p r e s s e d
ADA at the protein level (Figure 3A). As expected from
the promoter used to drive ADA expression, kidney
expression was restricted to the glomerulus.
Because introduction of the HA-tag could have altered
protein function, we evaluated ADA activity in the kid-
ney of transgenic mice from line 2 (ADA
tg). ADA activ-
ity was ~18-fold higher in ADA
tg mice than in wild
types (Figure 3B). It was also ~4-fold higher than in rat
kidney.
Effect of PAN
As previously reported [3,9], a single injection of
PAN (150 mg/kg body wt) to rats induced a marked
Figure 2 Expression of PMAT and ADA mRNAs in rat and
mouse glomerulus. Expression of mRNAs was quantitated by
QPCR on retro-transcribed mRNAs from microdissected mouse
(black columns) and rat (open columns) glomerulus. Values refer to
one glomerulus in either mouse or rat and are means ± SE from 5
mice and 6 rats. Statistical significance between groups was
assessed by unpaired Student’s t test: ***, p < 0.001.
Figure 3 Characterization of ADA transgenic mice.A .W e s t e r n
blot analysis of ADA expression. Expression of ADA was analyzed
using an anti-HA antibody in glomerulus (Gl), proximal convoluted
tubule (PCT) and cortical collecting duct (CCD) from two mice from
lines 2 (2.1 and 2.3) and 3 (3.6 and 3.9). Glomerulus from two wild
type mice (WT) served as negative controls. Only mice from line 2
expressed ADA, and expression was restricted to the glomerulus. B.
ADA activity in mouse and rat kidney. ADA activity was determined
in kidney homogenates from wild type mice, ADA
tg mice and
control rats. Values (units/mg tissue protein/min) are means ± SE
from several samples (number indicated above columns). Statistical
differences between groups were assessed by variance analysis:
***, p < 0.001.
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creatinine) and decreased sodium excretion (< 5 mmol/
mmol creatinine) (Figure 4A). Note that administration of
PAN induced a transient (day 1) increase in sodium excre-
tion which has been attributed to cytotoxicity. In contrast,
a single administration of PAN (150 mg/kg body wt) to
wild type mice did not alter significantly their urinary
excretion of proteins and sodium, except for the transient
increase in sodium excretion at day one (Figure 4B, dotted
lines). Note also that conversely to rats, mice displayed a
basal proteinuria, in the range of 0.5-2 g/mmol creatinine.
In ADA
tg mice, PAN neither increased proteinuria nor
induced marked sodium retention. However, it slightly
and transiently reduced sodium excretion, as compared
with wild type mice, at days 3 and 4 (Figure 4B, solid
lines). Extending the monitoring up to 14 days failed to
reveal proteinuria or sodium retention in either wild type
or ADA
tg mice (data not shown). Higher doses of PAN
(up to 300 mg/kg body wt) also failed to induce a nephro-
tic syndrome in either group of mice (data not shown)
In a final experimental series, we investigated whether
a second administration of PAN might amplify its
Figure 4 Effect of PAN treatment on urinary excretion of proteins and sodium. A. Effect of PAN in rats. PAN-treated (150 mg/kg body wt
at day 0, solid lines) and -untreated rats (dotted lines) were housed in metabolic cages and their daily excretion of sodium (circles) and proteins
(triangles) was monitored for 7 days. Results, expressed as a function of creatinine excretion, are means ± SE from 6 rats in each group. Statistical
significance between treated and untreated rats was assessed by unpaired Student’s t test: **, p < 0,025; ***, p < 0,001. B and C. Effect of PAN in
wild type and ADA
tg mice. Wild type (dotted lines) and ADA
tg mice (solid lines) received a single (B) or two (C) injections of PAN (150 mg/kg
body wt at day 0 and day 4, arrows) and were monitored for 7-10 days for urinary excretion of sodium (circles) and proteins (triangles). Results,
expressed as a function of creatinine excretion, are means ± SE from 6 mice in each group except the ADA
tg group treated once (n = 9). Values
statistically different from controls (day 0) were assessed by variance analysis followed by Bonferonni test: *, p < 0.05.
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nuria in ADA
tg mice. Figure 4C shows that two succes-
sive administrations of PAN (150 mg/kg body wt) at
days 0 and 4 failed to induce proteinuria or sodium
retention. In contrast, the two injections promoted a
transient increase in sodium excretion, attesting the effi-
ciency of PAN.
Discussion
PAN-induced nephrotic syndrome in rat has been
widely used for determining the structural alterations of
the filtration barrier responsible for proteinuria and the
functional changes responsible for tubular sodium reten-
tion. However, the mechanism of action of PAN is not
fully understood. PAN is thought to promote protei-
nuria through a cytotoxic effect on podocytes. Early
experiments in which a unilateral nephrotic syndrome
was induced by transient infusion of PAN in one kidney
while preventing its access to the general circulation
have demonstrated that proteinuria results from a rapid
and direct effect of PAN on the kidney. Several
observations suggest that PAN needs to be metabolized
to be nephrotoxic. Firstly, inhibition of ADA prevents
PAN-induced proteinuria in rats [13]. As a matter of
fact, PAN is a structural analogue of adenosine, the nat-
ural substrate of ADA (figure 5). However, PAN differs
from adenosine by an amino group substitution of the
hydroxyl group on carbon 3 of the ribose ring, and by a
dimethylamino substitution of the purine amino group.
Thus, it is unclear whether ADA catalyzes the deamina-
tion of the ribose or the removal of the dimethylamino
residue of the purine, or both. Secondly, PAN-induced
nephrotic syndrome is associated with the early produc-
tion of reactive oxygen species (ROS) in the glomerulus
[21-23] and treatment with ROS scavengers or antioxi-
dants reduces or prevents proteinuria [22,24,25]. Inter-
estingly, hypoxanthine is a metabolite of PAN [26]
generated by the removal of the dimethylamino residue
of the purine that acts as a substrate for ROS generation
by xanthine oxidase [24].
Because the resistance of mouse podocytes to PAN
was attributed to their deficiency in adenosine
Figure 5 Structure of adenosine, PAN and metabolites. Blue and red lettering indicate the structural differences between adenosine and
PAN, and the changes induced by ADA action respectively. ADA, adenosine deaminase; XO, xanthine oxidase; ROS, reactive oxygen species.
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mouse podocytes sensitive to PAN by promoting the
expression of the adenosine deamination pathway that
has been observed in rat podocytes. In order to be
metabolized by ADA, PAN first has to enter podocytes
via PMAT [14]. In this study we showed that PMAT is
expressed in mouse glomerulus at least at the same level
as in rat glomerulus, and through transgenesis we pro-
moted a podocyte ADA activity slightly higher than in
rat. Transgenesis was performed on FVB mice because
this background has proven to be more susceptible to
the development of proteinuria and ascites [27,28].
Nonetheless, whatever thed o s ea n d / o rt h en u m b e ro f
PAN injections, these ADA transgenic mice developed
neither proteinuria nor sodium retention. These results
suggest that PAN metabolism by ADA is not sufficient
to induce PAN sensitivity in mouse.
Over the past decade, many laboratories tried to
develop a mouse model mimicking human nephrotic
syndrome (Table 1). Three different strategies were
developed. The first one consisted in selecting or gener-
ating a genetic background to render mice sensitive to
PAN, as attempted in this study. The second one was to
induce proteinuria by altering the genetic expression of
proteins central to the filtration barrier. The last one
aimed at generating idiopathic nephrotic syndrome
through induction of the production of a permeability
factor by immune cells.
Results from the present study as well as several pre-
vious ones [13,29] have documented the resistance of
mouse to the nephrosis-inducing effect of PAN.
Increased sensitivity to PAN, in term of proteinuria, has
been reported in mice over expressing cycloxygenase-2
in a podocyte-specific manner (nephrin promoter) [29]
as well as in apolipoprotein E deficient, hypercholestero-
lemic mice [30]. However, in both cases, proteinuria was
moderate (3- to 5-fold increase) and was rapidly reversi-
ble as it was no longer detected after 8 days. In contrast,
Kanwar et al. reported over 30 years ago that repeated
administration of PAN induced a massive, nephrotic-
range proteinuria in hyperprolinemic mice (PRO/Re)
with a natural deficiency in proline oxidase [31]. The
possible link between PAN metabolism and proline oxi-
dase remains obscure and, curiously, these results have
never been confirmed since their publication, despite
the major interest in disposing of a mouse model of
nephrotic syndrome. No information is available regard-
ing sodium metabolism and/or edema or blood pressure
in any of these models.
To alter the glomerular filtration barrier, investigators
have targeted genes encoding proteins essential for the
structure and function of either the glomerular base-
ment membrane (laminin a5a n db2) or the podocytes
a n ds l i td i a p h r a g m( N p h s 2 ,C D 2 - A P ,C D 1 5 1a n d
a-actinin-4). Genetic inactivation of laminin a5 induced
a marked proteinuria in some but not all mice [32].
Laminin b2-deficient mice also displayed marked protei-
nuria, but the mice did not grow normally and died pre-
maturely [33]. A similar phenotype was developed by
a-actinin-4- or CD2-associated protein-deficient mice
[34,35]. These results clearly demonstrate the role of the
targeted genes in the filtration barrier, but prove that
the transgenic mouse lines generated are poor models
for studying the mechanism of sodium retention, mainly
because there is no evidence that these mice develop
edema and/or ascites. This is possibly due to the prema-
ture death of all these gene-targeted mice. To circum-
vent the growth deficit associated with proteinuria
during the development period, a model of inducible
inactivation of podocin based on Cre-loxP technology
was recently reported [36]. Interestingly, upon inactiva-
tion of podocin, these mice showed proteinuria,
Table 1 Animal models of proteinuria
Models Proteinuria Na handling Ref
Injection of PAN
Sprague Dawley rat 10 g/mmol creat Ascites,
edema
[9]
90 mg/mg creat Ascites,
edema
[9]
3 g/24 h/kg body wt Ascites,
edema
[9]
30 mg/ml Ascites,
edema
[9]
Wild type B6/D2
mouse
0.03 mg/mg creat [29]
ApoE
-/- mouse 0.2 mg/ml [30]
Cox2 tg mouse 0.07 mg/mg creat [29]
PRO/Re mouse 0.7 g/24 h/kg
body wt
[31]
Injection of adriamycin
Sprague Dawley rat 25 mg/mg creat Na retention [9]
B6/D2 mouse 0.04 mg/mg creat [41]
Balb/c mouse 23 mg/mg creat [42]
Balb/c mouse 226 mg/mg creat [43]
129 mouse 120 mg/mg creat Ascites [44]
Genetically modified mice
Laminin a5
-/- 200 mg/mg creat [32]
Laminin b2
-/- 12 mg/ml [33]
a-actinin-4
-/- + + [34]
Nphs2
-/- + + + HTA [36]
CD2-AP
-/- +++ [ 3 5 ]
CD151
-/- + + + Edema [27]
Human CD34
+
engraftment
NOD/SCID mouse 0.04 mg/mg creat [37]
Proteinuria in PAN nephrotic rats is given as a function of the different units
found in the literature. + + and + + + refers to increases in proteinuria as
determined by western blotting. When available, functional data related to
renal sodium handling are provided; HTA, hypertension.
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ascites or edema was described. In this model also, mice
died prematurely as the median survival was 11 weeks
following podocin loss. Mice with inactivation of
CD151, a tetraspanin involved in the adhesion of podo-
cytes to the basement membrane as well as in basement
membrane integrity, deserve a special attention. As a
matter of fact, CD151-deficient mice displayed marked,
although not quantified, albuminuria and survived for at
least 5 months. In addition, at this stage they were
reported to exhibit edema [27]. Unfortunately renal
function data (as opposed to morphological data) con-
cerning these mice are scarce.
The last strategy consisted in developing a humanized
model of nephrotic syndrome through engraftment of
CD34
+ cells from nephrotic patients in NOD/SCID
mice [37]. These mice developed mild proteinuria (3-
fold increase) and the model is too tedious to be used
routinely.
Adriamycin is also known to induce nephrotic syn-
drome in rat [38], and is often used to do the same in
mouse. In rats, adriamycin induces a clear-cut protei-
nuria within 1-2 weeks after injection, although to a
lesser extent than PAN. However, in terms of sodium
retention the effect of adriamycin is transient and
shows inter-individual differences in time-course [9],
making it a poor model to study this phenomenon. In
mouse, adriamycin-induced proteinuria is strain-depen-
dent, with most strains being quite resistant to adria-
mycin and few ones developing nephrotic-range
proteinuria within 1 week [39,40]. In an elegant study,
Zheng et al. used inter-strain differences to identify by
genome-wide analysis of linkage a locus on chromo-
some 16 associated with susceptibility to adriamycin,
but they failed to identify the responsible gene [40].
They also found a modifier locus on chromosome 9.
However, to our knowledge, sodium retention has not
been documented in adriamycin-treated mice. Regard-
ing tubular functions, a limit of the adriamycin model
is that sensitive mouse strains develop not only focal
segmental glomerulosclerosis but also tubulo-intersti-
tial fibrosis and tubular lesions that rapidly progress
towards renal insufficiency [40]. Thus, this is clearly
not a relevant model to study increased sodium
reabsorption.
Conclusions
Enhancing adenosine deaminase activity in podocytes is
not sufficient to render mice sensitive to PAN in terms
of nephrotic syndrome. The Ada
tg mouse line that we
have generated might be useful as background for future
attempts to transfer PAN-sensitivity in mice, since ade-
nosine deaminase activity remains necessary, but not
sufficient, to provide sensitivity to PAN.
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